How much did Cargene raise?

Cargene raised $13 Million in a Funding Round round on February 8, 2022.

Singapore-Based Biotech Startup Cargene Therapeutics Received $13 Million From Its Us-Based Affiliate Last Week.

PRIVATEFeb 08, 2022

Amount Raised

$13 Million

Round Type

Funding Round

SingaporeBiotechnologyHealth CareScience And Engineering

Description

Singapore-based biotech startup Cargene Therapeutics received $13 million from its US-based affiliate last week.

Quick answer

Cargene raised $13 Million in a Funding Round round, dated February 8, 2022. Cargene is based in Singapore.

How much did Cargene raise?: Cargene raised $13 Million in a Funding Round round on February 8, 2022.
What does Cargene do?: To tackle the most critical unmet need in NASH, Cargene has exclusively in-licensed regenerative medicine-related technology from Singapore's Agency for Science, Technology and Research (A*STAR) to reduce liver fibrosis..
Where is Cargene based and how big is it?: Cargene is based in Singapore.

Source: Fundz verified event record.

Who else raised in Science And Engineering and Biotechnology around the same time

Companies in the same sectors as Cargene that raised within 45 days of this round, from Fundz verified event records.

Geneos Therapeutics raised $17M (Series A) on March 24, 2022.
Nucleai raised $33M (Series B) on March 22, 2022.
Theriva Biologics raised $1.5M (Seed) on March 21, 2022.
Triumvira Immunologics Inc. raised an undisclosed amount (Series A) on March 17, 2022.
2seventy bio raised $170M (Post-IPO Equity) on March 16, 2022.
MAIA Biotechnology raised $2.4M (Seed) on March 16, 2022.

Who to call at Cargene, and when

A new round usually means Cargene is about to hire and buy. The teams that reach out first get the meeting.

An alert the day Cargene raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Cargene, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Cargene. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Cargene

Location

Singapore

About

To tackle the most critical unmet need in NASH, Cargene has exclusively in-licensed regenerative medicine-related technology from Singapore's Agency for Science, Technology and Research (A*STAR) to reduce liver fibrosis in NASH patients. Cargene is also developing technologies for targeted delivery of oligonucleotides to a variety of organs and tissues, and novel nucleosides to boost pharmaceutical efficacy of the siRNAs. Cargene was jointly founded by XQ Lin, Chairman and founder of EVX Ventures, Dr. Yann Chong Tan, a serial biotech entrepreneur who has co-founded a NASDAQ listed biotech company and Dr.Torsten Wuestefeld, principal investigator at A*STAR's Genome Institute of Singapore. Cargene has a scientific board of world-class scientists comprising Professors Harvey Lodish, Roger Foo, Kausik Ray, and Torsten Wuestefeld. Cargene has a founding team comprising biotech serial entrepreneurs and world-class experts in nucleic acid chemistry. Cargene is a preclinical-stage biopharmaceutical company developing oligonucleotide therapeutics for cardiovascular, fibrotic and pulmonary diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Cargene raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans

Predictive Intelligence

Strategic

ML-powered predictions for Cargene's next move

See what Strategic adds

Cargene raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

Show me how a sales rep uses this Or see plans and pricing →

5 screens from a live account. No signup.